“Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome”
TRIAL:
Clinical trial available now for topical gel to prevent basal cell skin cancers (BCCs) in people with Gorlin syndrome.
START DATE:
Ongoing at 30 sites worldwide.
ELIGIBILITY REQUIREMENTS:
These include the following:
LOCATIONS:
30 sites worldwide, over half across the United States. See below for a detailed site list with contact information.
EXPENSES:
All costs associated with your travel will be reimbursed fully. This includes air/bus/train fare, gas and tolls, meals, and overnight lodging as necessary. If a care partner is needed, this individuals’ expenses will be covered as well.
BENEFITS:
FOR MORE INFORMATION:
%20(2)-1.png?width=200&height=85&name=GSA%20Logo%20High%20Res%20No%20Background%20(1)%20(2)-1.png)